Cargando…

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

With the emergence and rapid spread of new pandemic variants, especially variants of concern (VOCs), the development of next-generation vaccines with broad-spectrum neutralizing activities is of great importance. In this study, SCTV01C, a clinical stage bivalent vaccine based on trimeric spike extra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rui, Sun, Chunyun, Ma, Juan, Yu, Chulin, Kong, Desheng, Chen, Meng, Liu, Xuejie, Zhao, Dandan, Gao, Shuman, Kou, Shuyuan, Sun, Lili, Ge, Zeyong, Zhao, Jun, Li, Kuokuo, Zhang, Tao, Zhang, Yanjing, Luo, Chunxia, Li, Xuefeng, Wang, Yang, Xie, Liangzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143086/
https://www.ncbi.nlm.nih.gov/pubmed/35632456
http://dx.doi.org/10.3390/vaccines10050702
_version_ 1784715718699253760
author Wang, Rui
Sun, Chunyun
Ma, Juan
Yu, Chulin
Kong, Desheng
Chen, Meng
Liu, Xuejie
Zhao, Dandan
Gao, Shuman
Kou, Shuyuan
Sun, Lili
Ge, Zeyong
Zhao, Jun
Li, Kuokuo
Zhang, Tao
Zhang, Yanjing
Luo, Chunxia
Li, Xuefeng
Wang, Yang
Xie, Liangzhi
author_facet Wang, Rui
Sun, Chunyun
Ma, Juan
Yu, Chulin
Kong, Desheng
Chen, Meng
Liu, Xuejie
Zhao, Dandan
Gao, Shuman
Kou, Shuyuan
Sun, Lili
Ge, Zeyong
Zhao, Jun
Li, Kuokuo
Zhang, Tao
Zhang, Yanjing
Luo, Chunxia
Li, Xuefeng
Wang, Yang
Xie, Liangzhi
author_sort Wang, Rui
collection PubMed
description With the emergence and rapid spread of new pandemic variants, especially variants of concern (VOCs), the development of next-generation vaccines with broad-spectrum neutralizing activities is of great importance. In this study, SCTV01C, a clinical stage bivalent vaccine based on trimeric spike extracellular domain (S-ECD) of SARS-CoV-2 variants Alpha (B.1.1.7) and Beta (B.1.351) with a squalene-based oil-in-water adjuvant was evaluated in comparison to its two corresponding (Alpha and Beta) monovalent vaccines in mouse immunogenicity studies. The two monovalent vaccines induced potent neutralizing antibody responses against the antigen-matched variants, but drastic reductions in neutralizing antibody titers against antigen-mismatched variants were observed. In comparison, the bivalent vaccine SCTV01C induced relatively higher and broad-spectrum cross-neutralizing activities against various SARS-CoV-2 variants, including the D614G variant, VOCs (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.1.529), variants of interest (VOIs) (C.37, B.1.621), variants under monitoring (VUMs) (B.1.526, B.1.617.1, B.1.429, C.36.3) and other variants (B.1.618, 20I/484Q). All three vaccines elicited potent Th1-biased T-cell immune responses. These results provide direct evidence that variant-based multivalent vaccines could play important roles in addressing the critical issue of reduced protective efficacy against the existing and emerging SARS-CoV-2 variants.
format Online
Article
Text
id pubmed-9143086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91430862022-05-29 A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants Wang, Rui Sun, Chunyun Ma, Juan Yu, Chulin Kong, Desheng Chen, Meng Liu, Xuejie Zhao, Dandan Gao, Shuman Kou, Shuyuan Sun, Lili Ge, Zeyong Zhao, Jun Li, Kuokuo Zhang, Tao Zhang, Yanjing Luo, Chunxia Li, Xuefeng Wang, Yang Xie, Liangzhi Vaccines (Basel) Article With the emergence and rapid spread of new pandemic variants, especially variants of concern (VOCs), the development of next-generation vaccines with broad-spectrum neutralizing activities is of great importance. In this study, SCTV01C, a clinical stage bivalent vaccine based on trimeric spike extracellular domain (S-ECD) of SARS-CoV-2 variants Alpha (B.1.1.7) and Beta (B.1.351) with a squalene-based oil-in-water adjuvant was evaluated in comparison to its two corresponding (Alpha and Beta) monovalent vaccines in mouse immunogenicity studies. The two monovalent vaccines induced potent neutralizing antibody responses against the antigen-matched variants, but drastic reductions in neutralizing antibody titers against antigen-mismatched variants were observed. In comparison, the bivalent vaccine SCTV01C induced relatively higher and broad-spectrum cross-neutralizing activities against various SARS-CoV-2 variants, including the D614G variant, VOCs (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.1.529), variants of interest (VOIs) (C.37, B.1.621), variants under monitoring (VUMs) (B.1.526, B.1.617.1, B.1.429, C.36.3) and other variants (B.1.618, 20I/484Q). All three vaccines elicited potent Th1-biased T-cell immune responses. These results provide direct evidence that variant-based multivalent vaccines could play important roles in addressing the critical issue of reduced protective efficacy against the existing and emerging SARS-CoV-2 variants. MDPI 2022-04-29 /pmc/articles/PMC9143086/ /pubmed/35632456 http://dx.doi.org/10.3390/vaccines10050702 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Rui
Sun, Chunyun
Ma, Juan
Yu, Chulin
Kong, Desheng
Chen, Meng
Liu, Xuejie
Zhao, Dandan
Gao, Shuman
Kou, Shuyuan
Sun, Lili
Ge, Zeyong
Zhao, Jun
Li, Kuokuo
Zhang, Tao
Zhang, Yanjing
Luo, Chunxia
Li, Xuefeng
Wang, Yang
Xie, Liangzhi
A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
title A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
title_full A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
title_fullStr A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
title_full_unstemmed A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
title_short A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants
title_sort bivalent covid-19 vaccine based on alpha and beta variants elicits potent and broad immune responses in mice against sars-cov-2 variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143086/
https://www.ncbi.nlm.nih.gov/pubmed/35632456
http://dx.doi.org/10.3390/vaccines10050702
work_keys_str_mv AT wangrui abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT sunchunyun abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT majuan abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT yuchulin abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT kongdesheng abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT chenmeng abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT liuxuejie abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhaodandan abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT gaoshuman abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT koushuyuan abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT sunlili abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT gezeyong abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhaojun abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT likuokuo abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhangtao abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhangyanjing abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT luochunxia abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT lixuefeng abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT wangyang abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT xieliangzhi abivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT wangrui bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT sunchunyun bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT majuan bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT yuchulin bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT kongdesheng bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT chenmeng bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT liuxuejie bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhaodandan bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT gaoshuman bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT koushuyuan bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT sunlili bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT gezeyong bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhaojun bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT likuokuo bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhangtao bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT zhangyanjing bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT luochunxia bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT lixuefeng bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT wangyang bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants
AT xieliangzhi bivalentcovid19vaccinebasedonalphaandbetavariantselicitspotentandbroadimmuneresponsesinmiceagainstsarscov2variants